| |
Original Artikel |
Datum |
Titel |
Autoren Max. 6 Autoren |
| 1 |
[GO] |
2024―Jan―07 |
新型コロナウイルス感染症下におけるクロマチン構造制御","Regulation of chromatin structure under COVID-19 |
Kinugasa Yasuha, Mara Anais Llamas-Covarrubias, Yumiko Imai |
| 2 |
[GO] |
2024―Jan―07 |
シングルセル情報とゲノム情報の統合解析によるCOVID-19重症化メカニズムの解明","Elucidating the mechanism of COVID-19 severity by integrative analyses of single-cell and host genetics data |
Edahiro Ryuya, Yuya Shirai, Yusuke Takeshima, Shuhei Sakakibara, Yuta Yamaguchi, Teruaki Murakami, Takayoshi Morita, Yasuhiro Kato, Yu-Chen Liu, Daisuke Motooka, James B Wing, Kyuto Sonehara, Yoshihiko Tomofuji, Ho Namkoong, Hiromu Tanaka, Ho Lee, Koichi Fukunaga, Haruhiko Hirata, Yoshito Takeda, Daisuke Okuzaki, Atsushi Kumanogoh, Yukinori Okada |
| 3 |
[GO] |
2024―Jan―07 |
An observational study of post COVID-19 syndrome in Japan using a medical database","メディカルデータベースを用いた日本における新型コロナウイルス感染症の後遺症研究 |
Kinugasa Yasuha, Mara Anais Llamas-Covarrubias, Katsuhiko Ozaki, Shinichi Higashiue, Yumiko Imai |
| 4 |
[GO] |
2024―Jan―07 |
COVID-19重症度予測シミュレーションと医療機械学習基盤(Medical MLOps)の構築","COVID-19 severity prediction orchestrated in medical MLOps |
Yachie Ayako, Yumiko Imai, Taiko Nishino, Sucheendra Kumar Palaniappan |
| 5 |
[GO] |
2024―Jan―07 |
新型コロナウイルスの進化","Evolution of SARS-CoV-2: Now And Then |
Kei Sato |
| 6 |
[GO] |
2024―Jan―07 |
New wave of airway 3D models: More than a proof-of-concept for pandemicpreparedness for industry |
Kazuhiro Ito |
| 7 |
[GO] |
2024―Jan―06 |
ACE2-from fly hearts to the heart of a pandemic","ACE2-from fly hearts to the heart of apandemic |
Josef Penninger |
| 8 |
[GO] |
2022―Dez―25 |
Inactivation of leukocytes for prevention of severe COVID-19 |
Mutoh-Matsushita Akiko |
| 9 |
[GO] |
2022―Dez―25 |
Depressive symptoms and cognitive dysfunction in Post Covid-19 Condition |
Noda Takamasa, Kaori Okabe, Yasunari Kanda, Motohiro Nishida |
| 10 |
[GO] |
2022―Dez―25 |
Population analysis approaches for the spread of covid-19 pandemic in 150 countries |
Koshimichi Hiroki |
| 11 |
[GO] |
2022―Dez―25 |
Increased levels of circulating cell-free DNA in COVID-19 patients with respiratory failure |
Katsuki Wakayama, Kiichi Nakahira, Akihiko Tanaka, Yosuke Hukuda, Jing Zhao, Shin Ohta, Hironori Sagara, Masanori Yoshizumi |
| 12 |
[GO] |
2022―Dez―25 |
Early prediction of severe COVID-19 progression by a novel lung injury-related biomarker protein |
Arakawa Noriaki |
| 13 |
[GO] |
2022―Dez―25 |
The prediction of therapeutic targets and microRNA network in the coronavirus pathogenesis pathway |
Shihori Tanabe, Sabina Quader, Ryuichi Ono, Horacio Cabral, Kazuhiko Aoyagi, Akihiko Hirose, Hiroshi Yokozaki, Hiroki Sasaki |
| 14 |
[GO] |
2022―Dez―25 |
Single cell multiomic analysis of PBMCs from SARS-COV-2 infected patients |
Mara Anais Llamas Covarrubias, Yasuha Kinugasa, Yutaka Suzuki, Yumiko Imai |
| 15 |
[GO] |
2022―Dez―25 |
ACE2-like carboxypeptidase B38-CAP suppresses severe acute lung injury induced by aspiration pneumonia and abdominal sepsis as well as SARS-CoV-2 infection |
Tomokazu Yamaguchi, Takafumi Minato, Midori Hoshizaki, Satoru Nirasawa, Jianbo An, Saori Takahashi, Yumiko Imai, Keiji Kuba |
| 16 |
[GO] |
2022―Dez―25 |
Development of a SARS-CoV-2 infection model using human iPSC-derived intestinal epithelium |
Yamada Shigeru, Takamasa Noda, Kaori Okabe, Shota Yanagida, Motohiro Nishida, Yasunari Kanda |
| 17 |
[GO] |
2022―Dez―25 |
Antiviral activity of curcumin and its analogs selected by artificial intelligence-supported activity prediction system in SARS-CoV-2-infected VeroE6 cells |
Hirotsugu Komatsu, Takeshi Tanaka, Zhengmao Ye, Ken Ikeda, Takao Matsuzaki, Tamotsu Shiroma, Masato Hosoda, Mayo Yasugi, Koji Teshima |
| 18 |
[GO] |
2022―Dez―25 |
Strategy for Development of Therapeutics for HIV/AIDS, Chronic Hepatitis B, and SARS-CoV-2/COVID-19 |
Hiroaki Mitsuya |
| 19 |
[GO] |
2022―Dez―25 |
Role of histone ubiquitination in SARS-CoV2 and influenza virus infection |
Kinugasa Yasuha, Midori Hoshizaki, Mara Llamas Covarrubias, Yumiko Imai |
| 20 |
[GO] |
2022―Mrz―20 |
Therapeutic effects of angiotensin converting enzyme 2 (ACE2) enzyme activity on acute lung injury in COVID-19 |
Tomokazu Yamaguchi, Midori Hoshizaki, Takafumi Minato, Satoru Nirasawa, Masamitsu Asaka, Mayumi Niiyama, Jianbo An, Daichi Utsumi, Satoshi Nagata, Haruhiko Kamada, Wataru Kamitani, Yoshihiro Kawaoka, Yasuhiro Yasutomi, Yumiko Imai, Keiji Kuba |
| 21 |
[GO] |
2022―Mrz―20 |
Development of Therapeutics for HIV/AIDS, CHB and COVID-19 |
Hiroaki Mitsuya |
| 22 |
[GO] |
2022―Mrz―20 |
Development of vaccines and therapeutics for COVID-19. |
Kiyama Ryuichi |
| 23 |
[GO] |
2022―Mrz―20 |
A new approach to combat the sepsis including COVID-19 by accelerating detoxification of hemolysis-related DAMPs |
Daiki Ousaka, Dengli Wang, Masahiro Nishiboli |
| 24 |
[GO] |
2022―Mrz―20 |
Human iPSC-based models to evaluate COVID-19 drugs |
Yasunari Kanda |
| 25 |
[GO] |
2022―Mrz―20 |
PMDA's efforts to promote medical innovation in the coronavirus pandemic |
Yasuhiro Fujiwara |
| 26 |
[GO] |
2022―Mrz―20 |
The coronavirus-related signaling pathway networks and prediction modeling with activity plots. |
Shihori Tanabe, Sabina Quader, Ryuichi Ono, Horacio Cabral, Kazuhiko Aoyagi, Akihiko Hirose, Hiroshi Yokozaki, Hiroki Sasaki |
| 27 |
[GO] |
2022―Mrz―20 |
Eco-pharma research focusing on ACE2-mediated SARS-CoV-2 entry |
Kato Yuri, Yasunari Kanda, Motohiro Nishida |
| 28 |
[GO] |
2022―Mrz―20 |
Characteristics of SARS-CoV-2 mRNA/LNP vaccines and their official verification |
Hanada Kentaro |
| 29 |
[GO] |
2022―Mrz―20 |
SARS-CoV-2 research using stem cell and organ-on-a-chip technologies |
Takayama Kazuo |
| 30 |
[GO] |
2022―Mrz―20 |
Establishment of SARS-CoV-2 respiratory tract infection model in CAG promoter-driven hACE2 transgenic mice |
Utsumi Daichi, Masamitsu Asaka, Haruhiko Kamada, Satoshi Nagata, Yutaka Nakachi, Tomokazu Yamaguchi, Yoshihiro Kawaoka, Keiji Kuba, Yasuhiro Yasutomi |
| 31 |
[GO] |
2022―Mrz―20 |
Development of artificial antibody against receptor binding domain of SARS-CoV-2 spike protein. |
Masahiro Oike, Hirotaka Takahashi, Tatsuya Sawasaki |
| 32 |
[GO] |
2021―Mrz―20 |
Construction of the multi-layer omics data generation / analysis platform that contributes to the precision medicine of COVID-19 |
Yumiko Imai |
| 33 |
[GO] |
2021―Mrz―20 |
Treatment of COVID-19 |
Kazuhiro Yatera |
| 34 |
[GO] |
2021―Mrz―20 |
Remdesivir for COVID-19 |
Yasuhisa Fujita |
| 35 |
[GO] |
2021―Mrz―20 |
COVID-19 Drug Candidate Pipeline, An Overview |
Hiroyuki Sugiyama |
| 36 |
[GO] |
2021―Mrz―20 |
Suppression of SARS-CoV-2-induced lung injury by ACE2-like carboxypeptidase B38-CAP in COVID-19 mouse model |
Tomokazu Yamaguchi, Takafumi Minato, Midori Hoshizaki, Masamitsu Asaka, Satoru Nirasawa, Mayumi Niiyama, Masaki Imai, Saori Takahashi, Daichi Utsumi, Jianbo An, Satoshi Nagata, Haruhiko Kamada, Yoshihiro Kawaoka, Yasuhiro Yasutomi, Yumiko Imai, Keiji Kuba |
| 37 |
[GO] |
2021―Mrz―20 |
Nationwide Emergency Survey Results on the Response to COVID-19 Pandemic and Its Effect on Pharmacological Education Conducted in the Department of Pharmacology in Universities and Colleges Jointly by the Physiology Society of Japan and the Japanese Pharmacological Society. |
Masaki Mogi, Tomoyuki Furuyashiki, Kazuhiro Takuma, Ken-ichi Otsuguro, Tomoyuki Tanaka, Masabumi Minami |
| 38 |
[GO] |
2021―Mrz―20 |
Eco-pharma research aimed at developing COVID-19 therapeutic agent |
Kato Yuri, Motohiro Nishida |
| 39 |
[GO] |
2021―Mrz―20 |
Drug repositioning to combat COVID-19 using artificial intelligence system |
Norihisa Shindo, Hiroyoshi Toyoshiba |
| 40 |
[GO] |
2021―Mrz―20 |
Drug Screening for COVID-19 using Supercomputer "Fugaku" |
Yasushi Okuno |
| 41 |
[GO] |
2021―Mrz―20 |
Contribution to Development of Remedies for COVID-19: Focusing on Eritoran |
Kappei Tsukahara |
| 42 |
[GO] |
2021―Mrz―20 |
Investigation of genetic variants in SARS-CoV-2-interacting molecules of ACE2, TMPRSS2 and TLR3/7/8 across populations |
Lee Ji-Won, In-Hee Lee, Sek Won Kong, Tadahiro Iimura |
| 43 |
[GO] |
2020―Mrz―17 |
Treatment to prevent the development of severe COVID-19 |
Yumiko Imai |
| 44 |
[GO] |
2020―Mrz―17 |
In silico approaches to drug repositioning for COVID-19 at AMED-BINDS |
Takatsugu Hirokawa, Sekijima Masakazu, Shigenori Tanaka, Haruki Nakamura |
| 45 |
[GO] |
2020―Mrz―17 |
Nonstructural proteins of Novel Coronavirus (SARS-CoV-2) |
Wataru Kamitani |
| 46 |
[GO] |
2020―Mrz―17 |
The initial response of the laboratory diagnosis team to SARS-CoV-2 in Japan and the current situation |
Makoto Takeda |
